YWYicong Wan

Yicong Wan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yicong Wan has a total of 14 co-authors. Here are the top co-authors by number of shared publications:

  • Yi Jiang

    Department of Gynecology, The First Affiliated Hospital of Nanjing Medical University

    2 shared publications
  • Huangyang Meng

    Department of Gynecology, The First Affiliated Hospital of Nanjing Medical University

    1 shared publication
  • Jingjing Ma

    The First Affiliated Hospital of Nanjing Medical University

    1 shared publication
  • Jinhui Liu

    Department of Gynecology, The First Affiliated Hospital of Nanjing Medical University

    1 shared publication
  • Jinsong Liu

    University of Texas M.D. Anderson Cancer Center

    1 shared publication
  • Lin Zhang

    Department of Gynecology The First Affiliated Hospital of Nanjing Medical University Nanjing Jiangsu China

    1 shared publication

Latest Publications

  • Open Access

    Exploration of a Novel Prognostic Risk Signatures and Immune Checkpoint Molecules in Endometrial Carcinoma Microenvironment

    by Jinhui Liu, Sipei Nie, Zhipeng Wu, Yi Jiang, Yicong Wan, Siyue Li, Huangyang Meng, Shulin Zhou, Wenjun Cheng

    The effectiveness of immunotherapy in treating endometrial carcinoma (EC) remains to be testified. In this study, we explored the underlying mechanism through tumor microenvironment (TME) and immune-related genes in EC. Based on The Cancer Genome Atlas (TCGA) database, we found 799 up-regulated and 139 down-regulated immune-related and differentially expressed genes of EC. Then, prognostic genes were screened out, functional annotations and interpreted interaction network of these genes were further investigated for the underlying regulation mechanisms. Moreover, by a conjoint Cox regression analysis, we built two risk models based on key prognostic immune-related genes, which identified respectively for overall survival and disease-free survival. Gene set enrichment analysis revealed immune-related pathways were mostly enriched in gene sets of the low-risk group, and the nomograms were constructed based on the risk models. We further explored the predictive value of risk signatures by exploring the tumor-infiltrating immune cells, prognostic immune checkpoints modulators, and checkpoint inhibitors in TME. We found higher immune cell infiltration and activation in low risk tumor tissues, which might cause lower tumor purity and contribute to better prognosis. Both the expression and immunophenoscore of immune checkpoints PD-1, CTLA4, PD-L1 and PD-L2 increased significantly in low-risk group. In addition, the low-risk group were found display higher tumor mutational burden. In summary, our study proved that high-immune TME might prevent the progression of EC, which indicated the possibility of immunotherapy to fight against EC. Funding Statement: National Natural Science Foundation (81472442, 81872119) and Jiangsu province medical innovation team (CXTDA2017008) supported our study. Declaration of Interests: The authors have no conflicts of interest to declare.

  • Upregulation HOXA10 homeobox gene in endometrial cancer: role in cell cycle regulation

    by Lin Zhang, Yicong Wan, Yi Jiang, Jingjing Ma, Jinsong Liu, Weiwei Tang, Xinru Wang, Wenjun Cheng

    Homeobox genes encode a group of transcription factors that regulate embryonic development, organ differentiation and cell proliferation. Some researchers found that homeobox gene family could regulate the expression of cell cycle-related factors which are involved in tumorigenesis. The aim of the present study was to determine whether HOXA10 gene could regulate the expression of p21 and control the cell cycle in endometrial cancer. Real-time PCR and Western blot were used to analyze HOXA10 and p21 gene expression in tissue samples of normal endometrium and endometrial cancer. Upregulate and downregulate HOXA10 gene in endometrial cancer cells by HOXA10-vector and HOXA10-siRNA, p21 mRNA and protein expression were tested by real-time PCR and Western blot. FCM analyze the cell cycle alteration, and cell count and EdU assay were recruited to detect cell proliferative activity after upregulation of HOXA10. Expression of HOXA10 and p21 gene decreased in endometrial cancer, and the expression level of HOXA10 was correlated with cancer grade. The percentage of G1 phase cells increased, and cell proliferative activity decreased after upregulate HOXA10 expression. The expression of p16, p27, Myc, Cyclin D1, Cyclin E, CDK2, CDK4 and CDK6 did not alter after upregulation HOXA10. P21 gene mRNA and protein increased/decreased after upregulation/downregulation HOXA10 expression in cancer cells. HOXA10 regulates G1 phase arrest in endometrial cancer which may be mediated by p21.